Journal Title：Nuclear Medicine And Biology

Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis, in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers. The importance of the target to an unmet clinical need should be the first consideration. If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized.

These multidisciplinary studies should validate the mechanism of localization whether the probe is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the probe to changes in disease or treatment, although studies validating mechanism alone are acceptable. Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field.

Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed.

《核醫(yī)學與生物學》發(fā)表涉及放射性藥物科學各個方面的原創(chuàng)研究：合成、體外和離體研究、通過解剖或成像進行的體內(nèi)生物分布、放射性藥理學、放射性藥理學以及新型靶向放射性示蹤劑的轉(zhuǎn)化臨床研究。靶標對未滿足的臨床需求的重要性應是首要考慮因素。如果提交的新型放射性藥物合成沒有體外或體內(nèi)數(shù)據(jù)，則必須強調(diào)化學的獨特性。

這些多學科研究應驗證定位機制，無論探針是基于與受體、酶、腫瘤抗原還是另一個明確定義的靶標的結(jié)合。研究應旨在評估化學和放射性藥物特性如何影響藥代動力學、藥效學或治療效果。理想情況下，研究將解決探針對疾病或治療變化的敏感性，盡管僅驗證機制的研究也是可以接受的。放射性藥物學實踐涉及制備、自動化、質(zhì)量控制、分配以及適用于放射性藥物對人體的鑒定和管理的法規(guī)等問題，是發(fā)展過程的一個重要方面，但前提是該研究對該領(lǐng)域有重大影響。

只要標記化合物定位和治療效果的特異性得到解決，那么關(guān)于治療性放射性藥物主題的貢獻也是合適的。

Nuclear Medicine And Biology創(chuàng)刊于1993年，由Elsevier Inc.出版商出版，收稿方向涵蓋醫(yī)學 - 核醫(yī)學全領(lǐng)域，此期刊水平偏中等偏靠后，在所屬細分領(lǐng)域中專業(yè)影響力一般，過審相對較易，如果您文章質(zhì)量佳，選擇此期刊，發(fā)表機率較高。平均審稿速度 一般,3-8周 約8周，影響因子指數(shù)3.6，該期刊近期沒有被列入國際期刊預警名單，廣大學者值得一試。